83 related articles for article (PubMed ID: 10649658)
1. Setting the record straight on PDR criticisms.
Mehta M
Postgrad Med; 2000 Jan; 107(1):22. PubMed ID: 10649658
[No Abstract] [Full Text] [Related]
2. The Physicians' Desk Reference. Problems and possible improvements.
Cohen JS; Insel PA
Arch Intern Med; 1996 Jul; 156(13):1375-80. PubMed ID: 8678706
[TBL] [Abstract][Full Text] [Related]
3. Editorial: limitations of the physicians' desk reference 2007.
Mindel JS; Teich SA; Teich CM; Beam P
Surv Ophthalmol; 2008; 53(1):82-4. PubMed ID: 18191659
[No Abstract] [Full Text] [Related]
4. Evolution of a children's drug table.
Shirkey HC
Hosp Formul; 1979 Mar; 14(3):319-20, 325-6, 330. PubMed ID: 10316796
[No Abstract] [Full Text] [Related]
5. [The therapeutic nightmare].
Olin GA; Göth E; Liljestrand A; Werkö L
Lakartidningen; 1966 Mar; 63(9):847-57. PubMed ID: 5919966
[No Abstract] [Full Text] [Related]
6. PDR provides latest Food and Drug Administration-approved dosage guidelines.
Mehta M
Arch Intern Med; 2001 Nov; 161(21):2622; author reply 2623. PubMed ID: 11718598
[No Abstract] [Full Text] [Related]
7. Cohen vs. PDR.
Rohde RA
Arch Intern Med; 2001 Nov; 161(21):2622-3; author reply 2623. PubMed ID: 11718599
[No Abstract] [Full Text] [Related]
8. Cancer myths. Setting the record straight.
Mayo Clin Womens Healthsource; 2004 Apr; 8(4):1-2. PubMed ID: 15088017
[No Abstract] [Full Text] [Related]
9. A record of accomplishment.
Provost GP
Am J Hosp Pharm; 1968 Jun; 25(6):269. PubMed ID: 5656771
[No Abstract] [Full Text] [Related]
10. Influencing standard setting.
Robinson JR
J Parenter Sci Technol; 1986; 40(3):77. PubMed ID: 3746573
[No Abstract] [Full Text] [Related]
11. Retrospective view of the interfacial relationship of the pharmaceutical industry with the Food and Drug Administration and the United States Pharmacopeia.
Hammer HF
J Parenter Sci Technol; 1984; 38(4):159-63. PubMed ID: 6491859
[No Abstract] [Full Text] [Related]
12. The Food and Drug Administration perspective: use of an investigational drug in a medical emergency.
Schultheis LW; Rappaport BA
Anesth Analg; 2007 Mar; 104(3):479-80. PubMed ID: 17312189
[No Abstract] [Full Text] [Related]
13. Medical costs and the drug industry.
Schwartz H
Med Times; 1981 Mar; 109(3):21s-24s, 28s. PubMed ID: 7207081
[No Abstract] [Full Text] [Related]
14. Manufacturing misdeeds cost Abbott record-breaking payment.
Lewis C
FDA Consum; 2000; 34(3):38-9. PubMed ID: 11521253
[No Abstract] [Full Text] [Related]
15. Medical costs and the drug industry.
Schwartz H
Wall St J Midwest Ed; 1980 Apr; 60(132):22. PubMed ID: 10245744
[No Abstract] [Full Text] [Related]
16. The evolution of new drug legislation.
Kelsey FO
BMQ; 1966 Sep; 17(3):72-81. PubMed ID: 5978212
[No Abstract] [Full Text] [Related]
17. View from the Nation's Capital.
Romansky MA
J Clin Psychopharmacol; 1984 Jun; 4(3):161-2. PubMed ID: 6096408
[No Abstract] [Full Text] [Related]
18. The importance of the state medical journal to the pharmaceutical industry.
Stetler CJ
J Med Assoc Ga; 1968 Feb; 57(2):73-7. PubMed ID: 5639734
[No Abstract] [Full Text] [Related]
19. Dietary supplements: background for dialogue between the industry and the medical profession.
Friede AI
Food Drug Law J; 1998; 53(3):413-20. PubMed ID: 10346719
[No Abstract] [Full Text] [Related]
20. The role of the medical director in the pharmaceutical industry.
Lyght CE
Curr Ther Res Clin Exp; 1975 Apr; 17(4):408-17. PubMed ID: 804390
[No Abstract] [Full Text] [Related]
[Next] [New Search]
